Video

Factors Informing Adjuvant Treatment Selection in HER2+ Early Breast Cancer

Author(s):

Joyce O’Shaughnessy, MD,Virginia Borges, MD

A look at how patient response to neoadjuvant treatment for HER2+ early breast cancer informs adjuvant treatment selection.

Related Videos
Sheldon M. Feldman, MD
In this episode of OncChats: Empowering Community Cancer Care, Dr. Rai emphasizes the importance of community outreach and support for patients with cancer, highlighting the need for holistic care that addresses both physiological and psychological aspects of treatment while reinforcing the value of strong relationships between primary care physicians and specialists.
In this episode of OncChats: Empowering Community Cancer Care, Dr. Woodworth sheds light on the “Road to Recovery” survivorship program at Henry Mayo, which supports cancer survivors by providing them with fitness, education, and mental health resources, and underscores the importance of mentorship programs for community providers to ensure equitable cancer care.
In this episode of OncChats: Empowering Community Cancer Care, Drs Woodworth and Rai, discuss their collaborative approach to cancer screening, emphasizing the importance of community efforts and individual assessments in integrating genetic testing and screenings into routine practice.
In this episode of OncChats: Empowering Community Cancer Care, experts discuss the significance of community-based cancer care, emphasizing that most cancers are diagnosed locally and highlighting the importance of collaboration between primary care physicians and specialists to provide optimal education and treatment.
Related Content
Shreeram Aradhye, MD, president, development, chief medical officer, Novartis
October 29th 2024

NCCN Guideline Update Recommends Adjuvant Ribociclib Plus AI in HR+/HER2– Early Breast Cancer

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Xiaojia Wang, MD, oncologist, Department of Breast Medical Oncology, Cancer Hospital, University of Chinese Academy of Sciences, Zhejiang Cancer Hospital
October 24th 2024

First-Line Ivonescimab Plus Chemotherapy Demonstrates Efficacy in Advanced TNBC

MedNews Week
September 4th 2024

Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer

Allison A. Aggon, DO, FACOS, Associate Professor, Division of Breast Surgery, Department of Surgery, Fox Chase Cancer Center
October 24th 2024

Fox Chase Cancer Center’s Dr. Allision Aggon Receives Earth Angel Award From Breast Cancer Nonprofit Organization

Ribociclib in breast cancer | Image Credit: © Axel Kock - stock.adobe.com
October 18th 2024

Ribociclib Earns Positive CHMP Opinion in HR+/HER2– Early Breast Cancer